FDA-Approved Device
1 in 4 patients with cognitive disorders is misdiagnosed. Our FDA-approved ERP/qEEG device provides the clarity physicians need.
What We Do
Clarimind assists neurologists and other physicians to effectively differentiate between dementia and depression, track disease progression and assess overall cognitive deficits associated with dementia and concussion/mTBI.
Our FDA-approved cognitive test is an objective biomarker system offering clarity in a field of complexity by facilitating an objective evaluation of patients with cognitive disorders.
Capabilities
Effectively differentiate between dementia and depression with objective biomarker data.
Detect deficits in the brain early in the disease process for better patient outcomes.
Monitor and track disease progression over time with quantifiable measurements.
Demonstrate that prescribed medications are working effectively through objective data.
Facilitate better return-to-environment decisions following head injury.
Predict disease course and outcome after a concussion or traumatic brain injury.
Explore
